Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Posts 16.5-Percent Drop in Revenues, Tripled Loss for Q4 of 2004

NEW YORK, Feb. 23 (GenomeWeb News) - Third Wave Technologies today reported a 16.5-percent drop in revenues and almost tripled losses for the fourth quarter of 2004.


The company had $8.1 million in revenues, down from $9.7 million during the same quarter in 2003. Third Wave said that more than half, or $4.7 million, of total revenues were derived from clinical molecular diagnostics, meaning that this business segment grew almost 90 percent compared to the fourth quarter of 2003.


R&D costs decreased to $2.9 million, from $3.8 million during the same period a year ago.


Third Wave's net loss for the quarter amounted to $4.7 million, or $.12 per share, up from $1.6 million, or $.04 per share, during the last quarter of 2003. This loss was primarily due to severance-related charges, non-recurring litigation, and Sarbanes-Oxley compliance expenses, according to the company.


The company said it plans to grow its USclinical molecular diagnostic revenues further in 2005. Third Wave is also finalizing plans for a multi-year agreement with private and government entities in Japanto perform extensive disease association studies. Though details of the study may not be available until early summer, the company anticipates deriving $10 million to $15 million in research product revenue from the project.


As of Dec. 31, Third Wave had $66.7 million in cash, cash equivalents, and short-term investments.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.